Innovation in Head & Neck Cancers!!! Dr. Mark Newman, CSO, GeoVax

In this week's BioTech Nation, we discuss Geovax, a company working on a novel approach to treat head and neck cancers, which are often difficult to treat after standard options have been exhausted. Geovax is developing A2 component therapy, using an enzyme delivered directly to the tumor by a needle injection, followed by an infusion of an inactive form of a chemotherapeutic drug, which becomes toxic to the tumors when processed by the enzyme. The treatment aims to localize the effects, reduce side effects, and potentially activate the immune system to target other tumor cells in the body. Phase two trials are underway, with promising results so far.